Cargando…
Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview
Respiratory viruses represent a major public health concern, as they are highly mutated, resulting in new strains emerging with high pathogenicity. Currently, the world is suffering from the newly evolving severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This virus is the cause of coron...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622998/ https://www.ncbi.nlm.nih.gov/pubmed/34835248 http://dx.doi.org/10.3390/vaccines9111317 |
_version_ | 1784605826123563008 |
---|---|
author | Al-Karmalawy, Ahmed A. Soltane, Raya Abo Elmaaty, Ayman Tantawy, Mohamed A. Antar, Samar A. Yahya, Galal Chrouda, Amani Pashameah, Rami Adel Mustafa, Muhamad Abu Mraheil, Mobarak Mostafa, Ahmed |
author_facet | Al-Karmalawy, Ahmed A. Soltane, Raya Abo Elmaaty, Ayman Tantawy, Mohamed A. Antar, Samar A. Yahya, Galal Chrouda, Amani Pashameah, Rami Adel Mustafa, Muhamad Abu Mraheil, Mobarak Mostafa, Ahmed |
author_sort | Al-Karmalawy, Ahmed A. |
collection | PubMed |
description | Respiratory viruses represent a major public health concern, as they are highly mutated, resulting in new strains emerging with high pathogenicity. Currently, the world is suffering from the newly evolving severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This virus is the cause of coronavirus disease 2019 (COVID-19), a mild-to-severe respiratory tract infection with frequent ability to give rise to fatal pneumonia in humans. The overwhelming outbreak of SARS-CoV-2 continues to unfold all over the world, urging scientists to put an end to this global pandemic through biological and pharmaceutical interventions. Currently, there is no specific treatment option that is capable of COVID-19 pandemic eradication, so several repurposed drugs and newly conditionally approved vaccines are in use and heavily applied to control the COVID-19 pandemic. The emergence of new variants of the virus that partially or totally escape from the immune response elicited by the approved vaccines requires continuous monitoring of the emerging variants to update the content of the developed vaccines or modify them totally to match the new variants. Herein, we discuss the potential therapeutic and prophylactic interventions including repurposed drugs and the newly developed/approved vaccines, highlighting the impact of virus evolution on the immune evasion of the virus from currently licensed vaccines for COVID-19. |
format | Online Article Text |
id | pubmed-8622998 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86229982021-11-27 Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview Al-Karmalawy, Ahmed A. Soltane, Raya Abo Elmaaty, Ayman Tantawy, Mohamed A. Antar, Samar A. Yahya, Galal Chrouda, Amani Pashameah, Rami Adel Mustafa, Muhamad Abu Mraheil, Mobarak Mostafa, Ahmed Vaccines (Basel) Review Respiratory viruses represent a major public health concern, as they are highly mutated, resulting in new strains emerging with high pathogenicity. Currently, the world is suffering from the newly evolving severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This virus is the cause of coronavirus disease 2019 (COVID-19), a mild-to-severe respiratory tract infection with frequent ability to give rise to fatal pneumonia in humans. The overwhelming outbreak of SARS-CoV-2 continues to unfold all over the world, urging scientists to put an end to this global pandemic through biological and pharmaceutical interventions. Currently, there is no specific treatment option that is capable of COVID-19 pandemic eradication, so several repurposed drugs and newly conditionally approved vaccines are in use and heavily applied to control the COVID-19 pandemic. The emergence of new variants of the virus that partially or totally escape from the immune response elicited by the approved vaccines requires continuous monitoring of the emerging variants to update the content of the developed vaccines or modify them totally to match the new variants. Herein, we discuss the potential therapeutic and prophylactic interventions including repurposed drugs and the newly developed/approved vaccines, highlighting the impact of virus evolution on the immune evasion of the virus from currently licensed vaccines for COVID-19. MDPI 2021-11-12 /pmc/articles/PMC8622998/ /pubmed/34835248 http://dx.doi.org/10.3390/vaccines9111317 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Al-Karmalawy, Ahmed A. Soltane, Raya Abo Elmaaty, Ayman Tantawy, Mohamed A. Antar, Samar A. Yahya, Galal Chrouda, Amani Pashameah, Rami Adel Mustafa, Muhamad Abu Mraheil, Mobarak Mostafa, Ahmed Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview |
title | Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview |
title_full | Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview |
title_fullStr | Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview |
title_full_unstemmed | Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview |
title_short | Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview |
title_sort | coronavirus disease (covid-19) control between drug repurposing and vaccination: a comprehensive overview |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622998/ https://www.ncbi.nlm.nih.gov/pubmed/34835248 http://dx.doi.org/10.3390/vaccines9111317 |
work_keys_str_mv | AT alkarmalawyahmeda coronavirusdiseasecovid19controlbetweendrugrepurposingandvaccinationacomprehensiveoverview AT soltaneraya coronavirusdiseasecovid19controlbetweendrugrepurposingandvaccinationacomprehensiveoverview AT aboelmaatyayman coronavirusdiseasecovid19controlbetweendrugrepurposingandvaccinationacomprehensiveoverview AT tantawymohameda coronavirusdiseasecovid19controlbetweendrugrepurposingandvaccinationacomprehensiveoverview AT antarsamara coronavirusdiseasecovid19controlbetweendrugrepurposingandvaccinationacomprehensiveoverview AT yahyagalal coronavirusdiseasecovid19controlbetweendrugrepurposingandvaccinationacomprehensiveoverview AT chroudaamani coronavirusdiseasecovid19controlbetweendrugrepurposingandvaccinationacomprehensiveoverview AT pashameahramiadel coronavirusdiseasecovid19controlbetweendrugrepurposingandvaccinationacomprehensiveoverview AT mustafamuhamad coronavirusdiseasecovid19controlbetweendrugrepurposingandvaccinationacomprehensiveoverview AT abumraheilmobarak coronavirusdiseasecovid19controlbetweendrugrepurposingandvaccinationacomprehensiveoverview AT mostafaahmed coronavirusdiseasecovid19controlbetweendrugrepurposingandvaccinationacomprehensiveoverview |